List view / Grid view
11 May 2015 | By Victoria White
Roche has announced that data from 10 of its approved cancer medicines and 10 of its investigational medicines will be presented at this year’s American Society of Clinical Oncology Annual Meeting (ASCO 2015).
7 May 2015 | By Victoria White
The FDA has granted Breakthrough Therapy Designation for venetoclax for the treatment of people who have relapsed or refractory CLL with 17p deletion...
8 April 2015 | By Victoria White
The EU has approved Avastin in combination with chemotherapy for the treatment of persistent, recurrent or metastatic carcinoma of the cervix...
11 March 2015 | By Roche
New option for patients as NICE accepts Gazyvaro® (obinutuzumab) for treatment of most common adult leukaemia...
4 March 2015 | By Roche
Roche announced that its Ordinary Annual General Meeting has voted in favour of all of the Board of Directors’ proposals...
2 March 2015 | By Roche
Combination of Avastin and chemotherapy would be the first new treatment in advanced cervical cancer to extend life in nearly a decade...
2 March 2015 | By Roche
Roche announced that it has extended the expiration of its tender offer to purchase up to 15,604,288 of the outstanding common shares of Foundation Medicine, Inc...
19 February 2015 | By Roche
Roche announced the U.S. Food and Drug Administration has accepted and granted priority review for the company’s New Drug Application for cobimetinib in combination with Zelboraf® (vemurafenib) for the treatment of people with BRAF V600 mutation-positive advanced melanoma...
9 February 2015 | By Roche
Roche announced that the U.S. Food and Drug Administration approved Lucentis® (ranibizumab injection) for the treatment of diabetic retinopathy, in people with diabetic macular edema...
4 February 2015 | By Roche
Roche announced positive results from the Phase III GADOLIN study, which evaluated treatment options for people with indolent non-Hodgkin’s lymphoma (iNHL) who are refractory to MabThera®/Rituxan® (rituximab) treatment...
3 February 2015 | By Roche
Roche today announced that it has commenced a cash tender offer for up to 15,604,288 outstanding shares of common stock of Foundation Medicine, Inc. at a price of $50.00 per share...
2 February 2015 | By Roche
US FDA has granted Breakthrough Therapy Designation for Roche’s investigational cancer immunotherapy MPDL3280A (anti-PDL1) in non-small cell lung cancer...
28 January 2015 | By Roche
Pharmaceutical giant Roche delivers its 2014 year-end results...
19 January 2015 | By Roche
Today Roche opened its new Learning Center in Kaiseraugst. Besides offering a superlative infrastructure for trainees, the Learning Center contains a state-of-the-art school laboratory, which in this form is unparalleled in Switzerland...
16 January 2015 | By Roche
Roche announced that it has agreed to acquire Trophos, a privately held biotechnology company based in Marseille, France...
